To understand the real-world clinical and economic burden in people with nonrelapsing secondary progressive multiple sclerosis (nrSPMS) in the United States (US).
No takes yet. Share an insight, caveat, or question.
Greene et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: